<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227694</url>
  </required_header>
  <id_info>
    <org_study_id>XCEL-M-09-01</org_study_id>
    <nct_id>NCT01227694</nct_id>
  </id_info>
  <brief_title>Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis</brief_title>
  <official_title>Articular Cartilage Regeneration in Gonarthrosis Grade II and III by Articular Infiltration of Xcel-m-condro-alpha.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Banc de Sang i Teixits</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro Medico Teknon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Terapia Regenerativa Tissular</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cetir Sant Jordi, S.a..</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Banc de Sang i Teixits</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, single-dose, single-arm phase I-II study in which 15
      patients diagnosed with gonarthrosis grade II-III (Kellgren and Lawrence) will enter the
      study with the primary objective of assessing the feasibility and safety of the knee
      articular infiltration of autologous bone marrow mesenchymal stem cells (MSC). Secondary
      objectives are to assess the efficacy by imaging procedures and clinical questionnaires.

      MSC obtained from each patient's bone marrow will be isolated and expanded &quot;Ex-Vivo&quot; under
      GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21
      days, patients will be implanted a single-dose of approximately 40 millions of autologous MSC
      in the knee by articular injection, and followed up for 12 month. Articular cartilage changes
      will be determined by T2-weighted MRI (Cartigram) at 6 and 12 month. Clinical assessment will
      measure the pain by the visual analogue scale (VAS), the self-reported functional status by
      Heath Assessment Questionnaire (HAQ), and the quality of life by Short Form 36 questionnaire
      (SF-36) at 3, 6 and 12 month.

      The working hypothesis proposes that the expected regenerative articular cartilage effect of
      the MSC will be produced to a measurable degree by imaging procedures and clinical
      questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of autologous bone marrow mesenchymal stem cells (MSC) knee articular infiltration.</measure>
    <time_frame>12 months</time_frame>
    <description>Feasibility will be assessed by checking the cascade of procedures (from bone marrow extraction to MSC implantation) and confirming the global process is viable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of autologous bone marrow mesenchymal stem cells (MSC) knee articular infiltration.</measure>
    <time_frame>12 months</time_frame>
    <description>Safety will be assessed by collecting adverse events throughout the experimental phase, including the follow-up at 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy by imaging procedures.</measure>
    <time_frame>6 months</time_frame>
    <description>Articular cartilage changes will be determined by T2-weighted MRI (Cartigram).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy by imaging procedures.</measure>
    <time_frame>12 month</time_frame>
    <description>Articular cartilage changes will be determined by T2-weighted MRI (Cartigram).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes.</measure>
    <time_frame>3 month</time_frame>
    <description>Clinical assessment will measure the pain by the visual analogue scale (VAS), the self-reported functional status by Heath Assessment Questionnaire (HAQ), and the quality of life by Short Form 36 questionnaire (SF-36).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes.</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical assessment will measure the pain by the visual analogue scale (VAS), the self-reported functional status by Heath Assessment Questionnaire (HAQ), and the quality of life by Short Form 36 questionnaire (SF-36).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes.</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical assessment will measure the pain by the visual analogue scale (VAS), the self-reported functional status by Heath Assessment Questionnaire (HAQ), and the quality of life by Short Form 36 questionnaire (SF-36).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Knee Injuries</condition>
  <condition>Joint Diseases</condition>
  <condition>Rheumatic Diseases</condition>
  <condition>Cartilage Diseases</condition>
  <arm_group>
    <arm_group_label>Autologous MSC knee implantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isolation and &quot;Ex-Vivo&quot; expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias Avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous MSC knee implantation</intervention_name>
    <description>Isolation and &quot;Ex-Vivo&quot; expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection.</description>
    <arm_group_label>Autologous MSC knee implantation</arm_group_label>
    <other_name>Xcel-m-condro-alpha</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Gonarthrosis grade II-III of Kellgren and Lawrence assessed by two observers

          2. Chronic knee pain with mechanical characteristics

          3. Absence of local or systemic septic process

          4. Haematological and biochemical laboratory tests without significant alterations that
             contraindicate treatment.

          5. Informed Consent form signed by the patient

          6. The patient is able to understand the nature of the study

        Exclusion Criteria:

          1. Patients &lt; 18 years or legally dependent

          2. Patients &gt;65 years

          3. Previous surgery of the knee

          4. Intraarticular treatment in the past 6 month

          5. Knee ligament or meniscus rupture observed by MRI

          6. Any sign of infection

          7. Positive serology for HIV-1 or HIV-2, Hepatitis B (HBsAg), Hepatitis C (Anti-HCV-Ab)
             and syphilis.

          8. Congenital or acquired malformation resulting in significant deformity of the knee and
             leading to problems in application or evaluation of results.

          9. Overweight expressed as body mass index (BMI) greater than 30.5 (obesity grade II).
             BMI estimated as mass (kg) / corporal surface (m2).

         10. Pregnant women or intend to become pregnant or breast-feeding

         11. Neoplasia

         12. Immunosuppressive states

         13. Participation in another clinical trial or treatment with a different investigational
             product within 30 days prior to inclusion in the study.

         14. Other pathologic conditions or circumstances that difficult participation in the study
             according to medical criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Soler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Teràpia Regenerativa Tissular (ITRT)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Medico Teknon-ITRT</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.itrt.es</url>
    <description>Institut de Terapia Regenerativa Tissular (ITRT), Barcelona, Spain</description>
  </link>
  <link>
    <url>http://www.bancsang.net</url>
    <description>Banc de Sang i Teixits</description>
  </link>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2010</study_first_submitted>
  <study_first_submitted_qc>October 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2010</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cell therapy</keyword>
  <keyword>Regenerative therapy</keyword>
  <keyword>Advance therapy</keyword>
  <keyword>Bone marrow</keyword>
  <keyword>Mesenchymal stem cell</keyword>
  <keyword>Autologous</keyword>
  <keyword>Interventional clinical trial</keyword>
  <keyword>Osteoarthrosis</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>Knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
    <mesh_term>Knee Injuries</mesh_term>
    <mesh_term>Cartilage Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

